SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS

Inclusion Criteria:

• Male or nonpregnant females aged 18-60 years old.

• Clinical diagnosis of tinea pedis (total sign/symptom score >2), lesions between thetoes, with possible extension to the lateral surfaces and soles of the feet confirmedby a positive microscopy prior to dosing.

• Willing to sign the informed consent.

Exclusion Criteria:

• Females who are pregnant (confirmed by a pregnancy test), suspect themselves to bepregnant (even if pregnancy test is negative), breast-feeding, or planning apregnancy.

• Signs of systemic or other superficial fungal disease (e.g.onychomycosis), clinicallyrelevant abnormal findings upon physical examination of the foot or previous treatmentwith a disallowed medication (such as corticosteroids).

• Presence of non-healing wounds and/or bacterial infection on the feet.

• Secondary bacterial infection due to tinea pedis

• Presence of pigmentation, extensive scarring, or pigmented lesions in the treatmentareas, which could interfere with the rating of efficacy parameters.

• History of hypersensitivity to any component of the test products.

• Current imuunosuppression. Specifically, these include patients with co-morbiditiessuch as diabetes, HIV, chronic diseases requiring maintenance medications, acutefebrile/infectious illnesses (i.e. Dengue, pneumonia, etc)

• Use within 3 months prior to baseline of: 1.) chemotherapy, or 2.) radiation therapy